Breaking News
Sort by:
Top Post
Roche’s Tecentriq Plus Avastin Reduced Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study
Roche has announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) […]
Aromatase Inhibitors Cut Breast Cancer Recurrence in Younger Patients
Drugs called aromatase inhibitors reduce the risk of breast cancer returning by compared with oestrogen […]
GenesisCare Enrolls First Patients to SpaceOAR Vue™ Hydrogel Global Clinical Trial
GenesisCare—one of the leading oncology providers in the United States, Australia, Spain and the United […]
Epic Sciences and Biosplice Therapeutics Announce Partnership for Metastatic Cancer Trials
Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for […]
HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate
HaemaLogiX Ltd (HaemaLogiX), the clinical-stage biotechnology company developing novel monoclonal antibody therapies for multiple myeloma, […]
Research Demonstrates Novel HIT Receptor Enhances T Cell Antigen Sensitivity and Elicits Superior Tumor Control
The journal Nature Medicine recently published a study in which researchers developed a novel receptor to enhance […]
Freenome Presents Research Highlighting its Multiomics Blood Testing Platform in PREEMPT CRC
Freenome, a privately held biotech company, presented at the American Society of Clinical Oncology Gastrointestinal […]
New Breast and Lung Cancer Treatments Approved in Scotland
3 new cancer treatments have now been approved by the Scottish Medicines Consortium (SMC) for […]
Lantern Pharma Announces Collaboration & Research Agreement with The Danish Cancer Society Research Center to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid Tumors
Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) platform […]
Avacta Selects Second pre|CISION™ Pro-drug Candidate for Development
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and […]
NeoCura and PhoreMost Announce Research Collaboration to Explore Novel Cancer Therapeutics
NeoCura Bio-Medical Technology Co., Ltd. (“NeoCura”), a leading RNA-based drug research and development company in […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more